BCL2 and precursor B-cell acute lymphoblastic leukemia: A recent study showed that, in a B-ALL patient-derived xenograft (PDX) model, hypodiploid cells are sensitive to the B-cell lymphoma (Bcl) 2 inhibitor Venetoclax (ABT-199), suggesting that Bcl2 inhibition could be a promising strategy for the treatment of hypodiploid B-ALL [6,11].